Lanean...
Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains
The characterization of kinases as oncogenic drivers has led to more than 30 FDA-approved targeted kinase inhibitors for cancer treatment. Unfortunately, these therapeutics fail to have clinical durability because of adaptive responses from the kinome and transcriptome that bypass inhibition of the...
Gorde:
| Argitaratua izan da: | Mol Cell Oncol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4845204/ https://ncbi.nlm.nih.gov/pubmed/27308566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1052182 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|